Advertisement

Breast Cancer Research and Treatment

, Volume 121, Issue 2, pp 431–437 | Cite as

Ki67: a time-varying biomarker of risk of breast cancer in atypical hyperplasia

  • Marta Santisteban
  • Carol Reynolds
  • Emily G. Barr Fritcher
  • Marlene H. Frost
  • Robert A. Vierkant
  • Stephanie S. Anderson
  • Amy C. Degnim
  • Daniel W. Visscher
  • V. Shane Pankratz
  • Lynn C. HartmannEmail author
Epidemiology

Abstract

Uncontrolled proliferation is a defining feature of the malignant phenotype. Ki67 is a marker for proliferating cells and is overexpressed in many breast cancers. Atypical hyperplasia is a premalignant lesion of the breast (relative risk ~ 4.0). Here, we asked if Ki67 expression could stratify risk in women with atypia. Ki67 expression was assessed immunohistochemically by digital image analysis in archival sections from 192 women with atypia diagnosed at the Mayo Clinic 1/1/67–12/31/91. Risk factor and follow-up data were obtained via study questionnaire and medical records. Observed breast cancer events were compared to population expected rates (Iowa SEER) using standardized incidence ratios (SIRs). We examined two endpoints: risk of breast cancer within 10 years and after 10 years of atypia biopsy. Thirty-two (16.7%) of the 192 women developed breast cancer over a median of 14.6 years. Thirty percent (58) of the atypias had ≥2% cells staining for Ki67. In these women, the risk of breast cancer within 10 years after atypia was increased (SIR 4.42 [2.21–8.84]) but not in those with <2% staining. Specifically, the cumulative incidence for breast cancer at 10 years was 14% in the high Ki67 vs. 3% in the low Ki67 group. Conversely, after 10 years, risk in the low Ki67 group rose significantly (SIR 5.69 [3.63–8.92]) vs. no further increased risk in the high Ki67 group (SIR 0.78 [0.11–5.55]). Ki67 appears to be a time-varying biomarker of risk of breast cancer in women with atypical hyperplasia.

Keywords

Atypical hyperplasia Breast cancer risk Ki-67 Immunohistochemistry 

Notes

Acknowledgments

This work was supported by NCI RO1 grant CA132879, Mayo Clinic Breast Cancer SPORE CA116201, and the Martha and Bruce Atwater Foundation. We thank Linda Murphy for immunostaining; Teresa Allers, Jo Johnson, Mary Campion, Melanie Kasner, and Romayne Thompson for data collection; Joel Worra for database development; Ann Harris and the Survey Research Center for patient follow-up; and Vicki Shea for assistance with manuscript preparation.

References

  1. 1.
    Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, Vierkant RA, Maloney SD, Pankratz VS, Hillman DW, Suman VJ, Johnson J, Blake C, Tlsty T, Vachon CM, Melton LJ 3rd, Visscher DW (2007) Benign breast disease and the risk of breast cancer. N Engl J Med 353(3):229–237CrossRefGoogle Scholar
  2. 2.
    Degnim AC, Visscher DW, Berman HK, Frost MH, Sellers TA, Vierkant RA, Maloney SD, Pankratz VS, de Groen PC, Lingle WL, Ghosh K, Penheiter L, Tlsty T, Melton LJ 3rd, Reynolds CA, Hartmann LC (2007) Stratification of breast cancer risk in women with atypia: a Mayo cohort study. J Clin Oncol 25(19):2671–2677CrossRefPubMedGoogle Scholar
  3. 3.
    London SJ, Connolly JL, Schnitt SJ, Colditz GA (1992) A prospective study of benign breast disease and the risk of breast cancer. JAMA 267(7):941–944CrossRefPubMedGoogle Scholar
  4. 4.
    Dupont WD, Page DL (1985) Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 312(3):146–151PubMedGoogle Scholar
  5. 5.
    Chlebowski RT (2000) Reducing the risk of breast cancer. N Engl J Med 343(3):191–198CrossRefPubMedGoogle Scholar
  6. 6.
    Pankratz VS, Hartmann LC, Degnim AC, Vierkant RA, Ghosh K, Vachon CM, Frost MH, Maloney SD, Reynolds C, Boughey JC (2008) Assessment of the accuracy of the gail model in women with atypical hyperplasia. J Clin Oncol 26(33):5374–5379CrossRefPubMedGoogle Scholar
  7. 7.
    Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57–70CrossRefPubMedGoogle Scholar
  8. 8.
    Gerdes J, Schwab U, Lemke H, Stein H (1983) Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31(1):13–20CrossRefPubMedGoogle Scholar
  9. 9.
    Allred DC, Mohsin SK, Fuqua SA (2001) Histological and biological evolution of human premalignant breast disease. Endocr Relat Cancer 8(1):47–61CrossRefPubMedGoogle Scholar
  10. 10.
    Rudas M, Neumayer R, Gnant MF, Mittelbock M, Jakesz R, Reiner A (1997) p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast. Eur J Cancer 33(1):39–44CrossRefPubMedGoogle Scholar
  11. 11.
    Shoker BS, Jarvis C, Davies MP, Iqbal M, Sibson DR, Sloane JP (2001) Immunodetectable cyclin D(1) is associated with oestrogen receptor but not Ki67 in normal, cancerous and precancerous breast lesions. Br J Cancer 84(8):1064–1069CrossRefPubMedGoogle Scholar
  12. 12.
    Imamura H, Haga S, Shimizu T, Watanabe O, Kajiwara T, Aiba M (1999) Prognostic significance of MIB1-determined proliferative activities in intraductal components and invasive foci associated with invasive ductal breast carcinoma. Br J Cancer 79(1):172–178CrossRefPubMedGoogle Scholar
  13. 13.
    Colozza M, Azambuja E, Cardoso F, Sotiriou C, Larsimont D, Piccart MJ (2005) Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol 16(11):1723–1739CrossRefPubMedGoogle Scholar
  14. 14.
    Balleine RL, Webster LR, Davis S, Salisbury EL, Palazzo JP, Schwartz GF, Cornfield DB, Walker RL, Byth K, Clarke CL, Meltzer PS (2008) Molecular grading of ductal carcinoma in situ of the breast. Clin Cancer Res 14(24):8244–8252CrossRefPubMedGoogle Scholar
  15. 15.
    Milanese TR, Hartmann LC, Sellers TA, Frost MH, Vierkant RA, Maloney SD, Pankratz VS, Degnim AC, Vachon CM, Reynolds CA, Thompson RA, Melton LJ 3rd, Goode EL, Visscher DW (2006) Age-related lobular involution and risk of breast cancer. J Natl Cancer Inst 98(22):1600–1607PubMedCrossRefGoogle Scholar
  16. 16.
    Page DL, Dupont WD, Rogers LW, Rados MS (1985) Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer 55(11):2698–2708CrossRefPubMedGoogle Scholar
  17. 17.
    Gooley TA, Leisenring W, Crowley J, Storer BE (1999) Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 18(6):695–706CrossRefPubMedGoogle Scholar
  18. 18.
    Visscher DW, Pankratz VS, Santisteban M, Reynolds C, Ristimaki A, Vierkant RA, Lingle WL, Frost MH, Hartmann LC (2008) Association between cyclooxygenase-2 expression in atypical hyperplasia and risk of breast cancer. J Natl Cancer Inst 100(6):421–427CrossRefPubMedGoogle Scholar
  19. 19.
    Liu S, Edgerton SM, Moore DH 2nd, Thor AD (2001) Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer. Clin Cancer Res 7(6):1716–1723PubMedGoogle Scholar
  20. 20.
    Natarajan L, Pu M, Parker BA, Thomson CA, Caan BJ, Flatt SW, Madlensky L, Hajek RA, Al-Delaimy WK, Saquib N, Gold EB, Pierce JP (2009) Time-varying effects of prognostic factors associated with disease-free survival in breast cancer. Am J Epidemiol 169(12):1463–1470CrossRefPubMedGoogle Scholar
  21. 21.
    Lundin J, Lehtimaki T, Lundin M, Holli K, Elomaa L, Turpeenniemi-Hujanen T, Kataja V, Isola J, Joensuu H (2006) Generalisability of survival estimates for patients with breast cancer-a comparison across two population-based series. Eur J Cancer 42(18):3228–3235CrossRefPubMedGoogle Scholar
  22. 22.
    Hess KR, Pusztai L, Buzdar AU, Hortobagyi GN (2003) Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat 78(1):105–118CrossRefPubMedGoogle Scholar
  23. 23.
    Adami HO, Graffman S, Lindgren A, Sallstrom J (1985) Prognostic implication of estrogen receptor content in breast cancer. Breast Cancer Res Treat 5(3):293–300CrossRefPubMedGoogle Scholar
  24. 24.
    Mason BH, Holdaway IM, Mullins PR, Yee LH, Kay RG (1983) Progesterone and estrogen receptors as prognostic variables in breast cancer. Cancer Res 43(6):2985–2990PubMedGoogle Scholar
  25. 25.
    Santen RJ, Mansel R (2005) Benign breast disorders. N Engl J Med 353(3):275–285CrossRefPubMedGoogle Scholar
  26. 26.
    Urruticoechea A, Smith IE, Dowsett M (2005) Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 23(28):7212–7220CrossRefPubMedGoogle Scholar
  27. 27.
    Ellis MJ, Tao Y, Young O, White S, Proia AD, Murray J, Renshaw L, Faratian D, Thomas J, Dowsett M, Krause A, Evans DB, Miller WR, Dixon JM (2006) Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol 24(19):3019–3025CrossRefPubMedGoogle Scholar
  28. 28.
    Torrisi R, Bagnardi V, Cardillo A, Bertolini F, Scarano E, Orland L, Mancuso P, Luini A, Calleri A, Viale G, Goldhirsch A, Colleoni M (2008) Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER—and/or PgR-positive breast cancer: clinical and biological activity. Br J Cancer 99(10):1564–1571CrossRefPubMedGoogle Scholar
  29. 29.
    Dowsett M, Dunbier AK (2008) Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res 14(24):8019–8026CrossRefPubMedGoogle Scholar
  30. 30.
    Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 90(18):1371–1388CrossRefPubMedGoogle Scholar
  31. 31.
    Riggs BL, Hartmann LC (2003) Selective estrogen-receptor modulators–mechanisms of action and application to clinical practice. N Engl J Med; 348(7):618–629CrossRefPubMedGoogle Scholar
  32. 32.
    Dunn BK, Wickerham DL, Ford LG (2005) Prevention of hormone-related cancers: breast cancer. J Clin Oncol 23(2):357–367CrossRefPubMedGoogle Scholar
  33. 33.
    Shaaban AM, Sloane JP, West CR, Foster CS (2002) Breast cancer risk in usual ductal hyperplasia is defined by estrogen receptor-alpha and Ki-67 expression. Am J Pathol 160(2):597–604PubMedGoogle Scholar
  34. 34.
    Hameed O, Ghali VS, Tartter PI, Mizrachi H (2005) Immunohistochemical staining for cyclin D1 and Ki-67 aids in the stratification of atypical ductal hyperplasia diagnosed on breast core biopsy. Am J Clin Pathol 124(6):862–872CrossRefPubMedGoogle Scholar
  35. 35.
    Cazzaniga M, Severi G, Casadio C, Chiapparini L, Veronesi U, Decensi A (2006) Atypia and Ki-67 expression from ductal lavage in women at different risk for breast cancer. Cancer Epidemiol Biomarkers Prev 15(7):1311–1315CrossRefPubMedGoogle Scholar
  36. 36.
    Khan QJ, Kimler BF, Clark J, Metheny T, Zalles CM, Fabian CJ (2005) Ki-67 expression in benign breast ductal cells obtained by random periareolar fine needle aspiration. Cancer Epidemiol Biomarkers Prev 14(4):786–789CrossRefPubMedGoogle Scholar
  37. 37.
    Bloom K, Harrington D (2004) Enhanced accuracy and reliability of HER-2/neu immunohistochemical scoring using digital microscopy. Am J Clin Pathol 121(5):620–630CrossRefPubMedGoogle Scholar
  38. 38.
    Tawfik OW, Kimler BF, Davis M, Donahue JK, Persons DL, Fan F, Hagemeister S, Thomas P, Connor C, Jewell W, Fabian CJ (2006) Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma. Histopathology 48(3):258–267CrossRefPubMedGoogle Scholar
  39. 39.
    Zhang K, Prichard JW, Yoder S, De J, Lin F (2007) Utility of SKP2 and MIB-1 in grading follicular lymphoma using quantitative imaging analysis. Hum Pathol 38(6):878–882CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2009

Authors and Affiliations

  • Marta Santisteban
    • 1
  • Carol Reynolds
    • 2
  • Emily G. Barr Fritcher
    • 2
  • Marlene H. Frost
    • 3
  • Robert A. Vierkant
    • 4
  • Stephanie S. Anderson
    • 4
  • Amy C. Degnim
    • 5
  • Daniel W. Visscher
    • 6
  • V. Shane Pankratz
    • 4
  • Lynn C. Hartmann
    • 3
    Email author
  1. 1.Department of OncologyClinica Universitaia de NavarraNavarraSpain
  2. 2.Department of Laboratory Medicine and Pathology, Mayo Clinic Cancer Center, Mayo Graduate School of Medical EducationMayo Clinic College of MedicineRochesterUSA
  3. 3.Division of Medical Oncology, Department of Oncology, Mayo Clinic Cancer Center, Mayo Graduate School of Medical EducationMayo Clinic College of MedicineRochesterUSA
  4. 4.Department of Health Sciences Research—Biostatistics, Mayo Clinic Cancer Center, Mayo Graduate School of Medical EducationMayo Clinic College of MedicineRochesterUSA
  5. 5.Department of General Surgery, Mayo Clinic Cancer Center, Mayo Graduate School of Medical EducationMayo Clinic College of MedicineRochesterUSA
  6. 6.Department of PathologyUniversity of MichiganAnn ArborUSA

Personalised recommendations